Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Karyopharm (Nasdaq: KPTI) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026.
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates.
Dial-in numbers are provided for domestic and international callers, and accompanying slides plus an archived webcast will be available on the company’s Investor "Events & Presentations" webpage about two hours after the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – KPTI
On Feb 5, the day this news came out, KPTI closed 3.33% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Share price
- $6.30
- Prior close before earnings date announcement
- Market cap
- $119,932,354
- Equity value prior to Feb 12, 2026 earnings call
- Resale registration shares
- 2,805,688 shares
- Resale S-3 filed Nov 3, 2025
- Outstanding shares
- 17,050,876 shares
- As of Oct 30, 2025 per shelf filing
- Affinity ownership
- 1,713,092 shares (8.6%)
- Schedule 13G/A as of Jan 22, 2026
- 2025 total revenue (prelim)
- $145 million
- Preliminary 2025 result per 8-K on Jan 12, 2026
- Q4 2025 revenue (prelim)
- $33 million
- Quarter ended Dec 31, 2025 per 8-K
- Cash & investments
- $64 million
- As of Dec 31, 2025 per 8-K
Historical Context
-
Reported 1,799 RSUs granted to new hires under inducement plan.
-
Preliminary 2025 revenue ≈ $145M and key 2026 Phase 3 data objectives.
-
Two new hires received 1,533 RSUs under 2022 Inducement Plan.
-
Announced virtual fireside chat participation in Baird’s Biotech Discovery Series.
-
Issued options on 2,800 shares and 15,791 RSUs to new employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET --
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-12-2026-302679676.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.